mProX™ Human ILDR2 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

ILDR2 has been studied in various applications. In the field of Alzheimer's disease (AD), ILDR2 has been investigated as a potential diagnostic biomarker. Expression analysis of inhibitory B7 family members, including ILDR2, in the peripheral blood of late-onset AD patients showed significantly higher levels of ILDR2 expression compared to healthy individuals. This suggests that ILDR2, along with other B7 family members, could serve as a diagnostic biomarker for identifying AD patients. In another study, ILDR2 was identified as a novel component of the kidney podocyte foot process. Proximity-dependent proteomics revealed the presence of ILDR2 in the podocyte foot process, indicating its potential role in maintaining foot process integrity. Additionally, ILDR2 expression was found to increase with age, suggesting its involvement in age-related changes in podocyte biology. ILDR2 has also been studied in the context of hyperlipidemia. A chromosome 1 substitution line, B6-Chr1BLD, was identified as a novel hyperlipidemia model, and ILDR2 was found to be associated with the abnormal metabolic phenotype observed in male B6-Chr1BLD mice. Furthermore, ILDR2 was shown to play a role in the regulation of intestinal barrier function and kidney inflammation in hyperuricemia rats. Marine fish protein peptide (MFPP) containing ILDR2 was found to alleviate kidney inflammation and restore kidney function in hyperuricemia rats. Lastly, ILDR2 was identified as a substrate of MALT1, a paracaspase involved in NF-κB signaling. The study utilized a bioinformatics-led substrate discovery workflow and identified ILDR2 as one of the new MALT1 substrates. These findings highlight the diverse applications of ILDR2 in different fields of research, including AD, kidney biology, hyperlipidemia, and protein function prediction.